In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. AptarGroup, Inc. is amongst them.
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing technologies, highlighted its growth strategy and long-term outlook during its Investor Day on September 9, 2025. Executive presentations emphasized strong momentum in the Pharma segment, driven by rising demand for innovative biologics, injectables, and patient-friendly drug delivery solutions.
In Q2 2025, AptarGroup, Inc. reported a 6% increase in revenue compared to the prior year, with net income rising 24% to $112 million and adjusted EBITDA up 13%. Earnings per share grew 25%, reflecting operational efficiencies and strong demand across the Pharma and Closures segments.
The company signaled confidence in its sustained performance by announcing a nearly 7% increase in its quarterly dividend to $0.48 per share, marking 32 consecutive years of dividend growth. AptarGroup, Inc. also returned $100 million to shareholders in dividends and share repurchases during the second quarter, totaling $210 million for the first half of the year, demonstrating a shareholder-friendly capital allocation approach.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
